Crinetics Pharmaceuticals, Inc.
CRNX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CRNX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRNX
Crinetics Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for endocrine diseases and endocrine-related tumors, with its lead candidate paltusotine under FDA review for acromegaly and a pipeline including candidates from a novel peptide-drug conjugate platform.
Key risk: Commercialization dependence
BioSniper Score
Based on 6 of 6 signals
Market Cap
$9.00B
Cash Runway
37.0 moLead Asset
atumelnant (Phase 1)
Next Catalyst
Phase3_Topline · Oct 1, 2026Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 267 clinical trials · 26 catalysts for Crinetics Pharmaceuticals, Inc..
Crinetics Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for endocrine diseases and endocrine-related tumors, with its lead candidate paltusotine under FDA review for acromegaly and a pipeline including candidates from a novel peptide-drug conjugate platform.
- Crinetics is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors [sec_mda · as of 2025-08-07].
- Lead product candidate paltusotine is under FDA review for the treatment of acromegaly [sec_mda · as of 2025-08-07].
- As of December 31, 2025, the company had cash, cash equivalents and investment securities of $1.0 billion; after a January 2026 public offering, pro forma cash was approximately $1.4 billion [sec_mda · as of 2026-02-26].
- In 2025, the company received IND clearance for CRN09682, the first candidate from its novel peptide-drug conjugate (NDC) platform, and the first patient was dosed in a Phase 1/2 study [sec_mda · as of 2026-02-26].
- Latest reported financials (as of 2026-06-30) show cash & equivalents of $56.3M, total revenue of $25.1M, net income of -$120.9M, and shareholders' equity of $1,171.5M [sec].
What works
- Crinetics has a robust pipeline of nonpeptide small molecules targeting peptide GPCRs, with expertise in endocrine diseases [sec_mda · as of 2025-08-07].
- The company has a strong cash position, with approximately $1.4 billion in cash, cash equivalents and investment securities after a January 2026 public offering, providing a multi-year runway [sec_mda · as of 2026-02-26].
- Paltusotine received FDA approval for acromegaly in September 2025, marking a key commercial milestone [sec · filed 2026-04-29].
- The novel peptide-drug conjugate platform (NDC) has advanced to the clinic with CRN09682, expanding the company's technology base [sec_mda · as of 2026-02-26].
What to weigh
- The company has a history of significant net losses, with a net loss of $120.9M for the six months ended June 30, 2026 [sec].
- Crinetics is heavily dependent on the successful commercialization of paltusotine and the clinical success of its pipeline candidates, which are still in early stages [sec_mda · as of 2025-08-07].
- The company faces risks related to intellectual property protection, regulatory approvals, and competitive pricing [sec · filed 2026-04-29].
- Forward-looking statements indicate that actual results may vary materially from projections, and capital may be used sooner than expected [sec_mda · as of 2026-05-07].
From the filings
Quoted directly from source documents.
Crinetics is a clinical-stage company focused on endocrine diseases and endocrine-related tumors.
“We are a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors.”
SEC MD&A · August 7, 2025
Paltusotine is under FDA review for acromegaly.
“Our lead product candidate is paltusotine, which is under review by the U.S. Food and Drug Administration, or FDA, in the United States, or U.S., for the treatment of acr”
SEC MD&A · August 7, 2025
Cash position was approximately $1.4 billion after a January 2026 public offering.
“After the completion of this public offering, the Company had approximately $1.4 billion in cash, cash equiv”
SEC MD&A · February 26, 2026
CRN09682, the first NDC platform candidate, entered the clinic in 2025.
“In November 2025, the first patient received CRN09682 in the dose escalation phase of a Phase 1/2 study.”
SEC MD&A · February 26, 2026
Catalyst timeline
- 2026-10-01 · Phase3_Topline · senseye — Phase 3 Topline: Diagnostic Testing of Post-Traumatic Stress Disorder (PTSD) Using the Senseye Diagnostic Tool in Adu — Topline results from a Phase 3 trial evaluating the Senseye diagnostic tool for PTSD will be reported.
- 2026-12-01 · Phase3_Topline — Phase 3 Topline: Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Plac — Topline results from a Phase 3 trial comparing apremilast versus placebo will be disclosed.
- 2026-12-20 · Phase3_Topline · dalargin — Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled Trial of Dalargin for the Prevention of Postoperative — Topline results from a Phase 3 trial of dalargin for postoperative prevention will be released.
- 2026-12-31 · Phase3_Topline — Phase 3 Topline: Randomized Prospective Study Comparing Intrathecal Morphine vs Intravenous Methadone for Postoperati — Topline results from a Phase 3 trial comparing intrathecal morphine versus intravenous methadone will be reported.
- 2026-12-31 · Phase3_Topline · raphamin — Phase 3 Topline: Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Effi — Topline results from a Phase 3 trial of raphamin will be disclosed.
- 2027-04-01 · Phase3_Topline — Phase 3 Topline: Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Univer — Topline results from a Phase 3 trial on an immune-guided CMV prevention strategy will be reported.
- 2027-04-30 · Phase3_Topline — Phase 3 Topline: Efficacy of Post-Surgical Stereotactic Radiosurgery for Metastatic Brain Disease: A Randomized Trial — Topline results from a Phase 3 trial on post-surgical stereotactic radiosurgery for metastatic brain disease will be released.
- 2027-05-01 · Phase3_Topline — Phase 3 Topline: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficac — Topline results from a Phase 3 trial evaluating safety and efficacy of an undisclosed treatment will be disclosed.
Risks & what to watch (4)›
Key risks
- Commercialization dependence — Crinetics' near-term success hinges on paltusotine's commercial launch and market acceptance for acromegaly [sec · filed 2026-04-29].
- Clinical and regulatory uncertainty — Pipeline candidates are in early-stage trials; delays or failures in clinical development could impair value [sec_mda · as of 2026-02-26].
- Intellectual property challenges — The company may not be able to obtain, maintain or enforce patents, which could affect competitive position [sec · filed 2026-04-29].
- Capital consumption risk — Despite a strong cash position, operating losses and high R&D costs could deplete resources faster than projected [sec_mda · as of 2026-05-07].
What to watch
- FDA decision on paltusotine for acromegaly, expected in 2025 [sec_mda · as of 2025-08-07].
- Phase 1/2 data for CRN09682, the first NDC platform candidate, as patient dosing began in November 2025 [sec_mda · as of 2026-02-26].
- Commercial launch performance of paltusotine following FDA approval in September 2025 [sec · filed 2026-04-29].
- Financial updates, particularly cash runway and revenue from paltusotine sales, in upcoming quarterly reports [sec_mda · as of 2026-05-07].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Crinetics Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Crinetics Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
37.0 months
D/E 0.11 · 0% dilution
Lead: Approved
3 candidates
26 upcoming, next in ~32d
0 buys · 14 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
242
Total value held
$4.32B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 15,759,799 | $572.4M |
| vanguard capital management llc | 9,347,870 | $339.5M |
| janus henderson group plc | 9,040,502 | $328.5M |
| blackrock, inc. | 8,478,815 | $308.0M |
| farallon capital management llc | 8,338,098 | $302.8M |
| wellington management group llp | 8,157,204 | $296.3M |
| driehaus capital management llc | 6,395,922 | $232.3M |
| vanguard portfolio management llc | 4,638,511 | $168.5M |
| bellevue group ag | 3,280,000 | $119.1M |
| geode capital management, llc | 2,480,763 | $90.1M |
Showing top 10 of 242 institutional holders of Crinetics Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 15.7%
- Days to cover
- 13.0
- Shares short
- 14,170,153
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRNX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Crinetics Pharmaceuticals, Inc.?
Crinetics Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for endocrine diseases and endocrine-related tumors, with its lead candidate paltusotine under FDA review for acromegaly and a pipeline including candidates from a novel peptide-drug conjugate platform.
What is Crinetics Pharmaceuticals, Inc.'s lead drug candidate?
Crinetics Pharmaceuticals, Inc.'s most advanced tracked candidate is atumelnant (Phase 1) for Congenital Adrenal Hyperplasia; Cushing Syndrome; Healthy Volunteers.
What is Crinetics Pharmaceuticals, Inc.'s next catalyst?
Crinetics Pharmaceuticals, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Diagnostic Testing of Post-Traumatic Stress Disorder (PTSD) Using the Senseye Diagnostic Tool in Adu" — expected October 1, 2026.
Who is the CEO of Crinetics Pharmaceuticals, Inc.?
Dr. R. Scott Struthers Ph.D. is the chief executive officer of Crinetics Pharmaceuticals, Inc. (CRNX).
Where is Crinetics Pharmaceuticals, Inc. headquartered?
Crinetics Pharmaceuticals, Inc. (CRNX) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.